Global Inflammatory Bowel Disease Market Growth (Status and Outlook) 2023-2029

Global Inflammatory Bowel Disease Market Growth (Status and Outlook) 2023-2029

Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine. Crohn's diseaseand ulcerative colitis are the principal types of inflammatory bowel disease. Crohn's disease affects the small intestine and large intestine, as well as the mouth, esophagus, stomach and the anus, whereas ulcerative colitis primarily affects the colon and the rectum.

LPI (LP Information)' newest research report, the “Inflammatory Bowel Disease Industry Forecast” looks at past sales and reviews total world Inflammatory Bowel Disease sales in 2022, providing a comprehensive analysis by region and market sector of projected Inflammatory Bowel Disease sales for 2023 through 2029. With Inflammatory Bowel Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Inflammatory Bowel Disease industry.

This Insight Report provides a comprehensive analysis of the global Inflammatory Bowel Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Inflammatory Bowel Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Inflammatory Bowel Disease market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Inflammatory Bowel Disease and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Inflammatory Bowel Disease.

The global Inflammatory Bowel Disease market size is projected to grow from US$ 12530 million in 2022 to US$ 16080 million in 2029; it is expected to grow at a CAGR of 3.6% from 2023 to 2029.

Medical treatment of IBD is individualised to each patient. The choice of which drugs to use and by which route to administer them (oral, rectal, injection, infusion) depends on factors including the type, distribution, and severity of the patient's disease, as well as other historical and biochemical prognostic factors, and patient preferences. For example, mesalazine is more useful in ulcerative colitis than in Crohn's disease. Generally, depending on the level of severity, IBD may require immunosuppression to control the symptoms, with drugs such as prednisone, TNF inhibitors, azathioprine (Imuran), methotrexate, or 6-mercaptopurine.

This report presents a comprehensive overview, market shares, and growth opportunities of Inflammatory Bowel Disease market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Aminosalicylates
Antibiotics
Corticosteroids
Biologic therapies (biological drugs)
Others

Segmentation by application
Hospital
Clinic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bristol-Myers Squibb Company
Baxter International
Johnson & Johnson
Sanofi-Aventis
Abbott Laboratories
Pluristem Therapeutics
Pfizer
AstraZeneca
Cephalon
Amgen

Please note: The report will take approximately 2 business days to prepare and deliver.